Adorno Febles Victor R, Blacksburg Seth, Haas Jonathan A, Wise David R
Perlmutter Cancer Center, Langone Medical Center, New York University, New York, NY, United States.
New York University Winthrop Hospital, Mineola, NY, United States.
Front Oncol. 2020 May 27;10:830. doi: 10.3389/fonc.2020.00830. eCollection 2020.
Stereotactic body radiotherapy (SBRT) is an increasingly used radiation modality for the treatment of both localized and metastatic prostate cancer. Substantial data suggests that prostate cancer may be more sensitive to higher doses of radiation per fraction due to its low α/β ratio. This increased sensitivity raises important questions as to how SBRT should be combined with systemic therapy for clinically significant prostate cancer, including whether androgen deprivation therapy retains its beneficial effects when combined with SBRT. Furthermore, pre-clinical and clinical data suggest pronounced immunomodulatory effects of SBRT, including observed improvements in T cell priming and trafficking. These data support investigational strategies combining SBRT with immunotherapy. Here we aim to review the data for the use of SBRT in both the local and metastatic disease settings as well as ongoing translational and clinical research examining combinations with ADT, immunotherapy and other targeted agents.
立体定向体部放疗（SBRT）是一种越来越多地用于治疗局限性和转移性前列腺癌的放疗方式。大量数据表明，由于前列腺癌的α/β比值较低，其可能对每分次更高剂量的放疗更敏感。这种增加的敏感性引发了一些重要问题，即SBRT应如何与针对具有临床意义的前列腺癌的全身治疗相结合，包括雄激素剥夺治疗与SBRT联合使用时是否仍保持其有益效果。此外，临床前和临床数据表明SBRT具有显著的免疫调节作用，包括观察到的T细胞启动和迁移的改善。这些数据支持将SBRT与免疫疗法相结合的研究策略。在这里，我们旨在回顾SBRT在局部和转移性疾病环境中的使用数据，以及正在进行的关于与雄激素剥夺治疗、免疫疗法和其他靶向药物联合使用的转化和临床研究。
